Selinexor’s Immunomodulatory Impact in Advancing Multiple Myeloma Treatment

Authors: Kereshmeh Tasbihi, Heiko Bruns

Source: Cells, Vol 14, Iss 6, p 430 (2025)

Subject Terms: Selinexor, XPOVIO, XPO1, Exportin-1, nuclear export, multiple myeloma, Cytology, QH573-671

File Description: electronic resource

Relation: https://www.mdpi.com/2073-4409/14/6/430; https://doaj.org/toc/2073-4409

Access URL: https://doaj.org/article/52124205c2794d52a0146760fbb907fa

Antengene Announces 2024 Full-Year Financial Results, Proprietary Programs Advancing to Pivotal Trials with Accelerating Multi-market Revenue Ramp Up

Source: PR Newswire. March 21, 2025

XPOVIO Continues to Disrupt the Oncology Market with Expanded Indications and Strong Market Performance | DelveInsight

Source: PR Newswire. March 5, 2025

XPOVIO (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Source: PR Newswire. March 5, 2025

Karyopharm Announces 1-for-15 Reverse Stock Split

Source: PR Newswire. February 24, 2025

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Source: PR Newswire. February 19, 2025

Antengene Announces XPOVIO Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Source: PR Newswire. February 13, 2025

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Source: PR Newswire. January 13, 2025

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Source: PR Newswire. January 2, 2025

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Source: PR Newswire. December 9, 2024

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Source: PR Newswire. December 3, 2024

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Source: PR Newswire. November 5, 2024

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Source: PR Newswire. November 5, 2024

US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma

Authors: Dolph M, Tremblay G, Leong H

Source: ClinicoEconomics and Outcomes Research, Vol Volume 13, Pp 493-502 (2021)

Subject Terms: budget impact, multiple myeloma, xpovio, selinexor, xvd, relapsed or refractory multiple myeloma, Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.dovepress.com/us-budget-impact-model-for-selinexor-bortezomib-and-dexamethasone-for--peer-reviewed-fulltext-article-CEOR; https://doaj.org/toc/1178-6981

Access URL: https://doaj.org/article/b290933190d74946879c25d35717c86c

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Source: PR Newswire. October 31, 2024

Antengene Announces XPOVIO (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Source: PR Newswire. October 17, 2024

Antengene Announces XPOVIO (selinexor) Approved for Commercialization in Thailand

Source: PR Newswire. September 23, 2024

Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization

Source: PR Newswire. August 23, 2024

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Source: PR Newswire. August 6, 2024

Antengene Announces XPOVIO (selinexor) Approved for Commercialization in Malaysia

Source: PR Newswire. August 5, 2024